Efficacy of rebamipide enemas in active distal ulcerative colitis and proctitis: A prospective study report

Digestive Diseases and Sciences

Volumn 50, Issue 12, 2005, Pages 2323-2329

  Makiyama, K ^a   Takeshima, F ^a   Hamamoto, T ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Distal ulcerative colitis; Rebamipide; Topical therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; REBAMIPIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEFECATION; DRUG EFFICACY; FEMALE; HUMAN; INTESTINE MUCOSA; LEUKOCYTE ACTIVATION; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTI-ULCER AGENTS; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOSCOPY, GASTROINTESTINAL; ENEMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROBABILITY; PROCTITIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 30844471588     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-3055-1     Document Type: Article

References (37)

1. Allison MC, Dhillon AP, Lewis WG, Pounder RE (eds): Inflammatory Bowel Disease. London, Mosby, 1998, pp 15-95
2. Babb RR: Corticosteroids in ulcerative colitis: A skeptical view. J Clin Gastroenterol 10:365-367, 1988
3. Present DH: How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 6:48-57, 2000
4. Hanai H, Watanabe F, Takeuchi K, Saniabadi A, Bjarnason I: Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled study. Clin Gastroenterol Hepatol 1:28-35, 2003
5. Shanahan F: Inflammatory bowel disease: Immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 120:622-635, 2001
6. Yamamoto T, Umegae S, Kitagawa T, Yasuda Y, Yamada Y, Takahashi D, Mukumoto M, Nishimura N, Yasue K, Matsijimoto K: Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment Pharmacol Ther 20:783-792, 2004
7. Treulove SC: Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium: a report on a controlled therapeutic trial. Br Med J 2:1072-1077, 1958
8. Campieri M, Gionchetti P, Belluzzi A, Brignola C, Tampieri M, Iannone P, Miglioli M, Barbara L: Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut 32:929-931, 1991
9. Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, Martin T, Sparr J, Prokipchuk ED, Borgen L: 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 92:1894-1898, 1987
10. Bianchi Porro G, Ardizzone S, Petrillo M, Fasoli A, Molteni P, Imbesi V: Low Pentasa dosage versus hydrocortisone in the topical treatment of active ulcerative colitis: A randomized, double-blind study. Am J Gastroenterol 90:736-739, 1995
11. Hanauer SB (for the U.S. PENTASA Enema Study Group): Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: Results of multicentered placebo-controlled trial. Inflamm Bowel Dis 4:79-83, 1998
12. Selby WS, Bennett MK, Jewell DP: Topical treatment of distal ulcerative colitis with 4-amino-salicylic acid enemas. Digestion 29:231-234, 1984
13. Ryder SD, Walker RJ, Jones H, Rhodes JM: Rectal bismuth subsalicylate as therapy for ulcerative colitis. Aliment Pharmacol Ther 4:333-338, 1990
14. Pullan RD, Ganesh S, Mani V, Morris J, Evans BK, Williams GT, Rhodes J: Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial. Gut 34:676-679, 1993
15. Bjorck S, Dahlstrom A, Ahlman H: Topical treatment of ulcerative colitis with lidocaine. Scand J Gastroenterol 24:1061-1072, 1989
16. Sandborn WJ, Tremaine WJ, Schroeder KW, Batts KP, Lawson GM, Steiner BL, Harrison JM, Zinsmeister AR: A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 106:1429-1435, 1994
17. Zea-Iriarte WL, Makiyama K, Goto S, Murase K, Urata Y, Sekine I, Hara K, Kondo T: Impairment of antioxidants in colonic epithelial cells isolated from trinitrobenzene sulphonic acid-induced colitis rats. Scand J Gastroenterol 31:985-992, 1996
18. Genta RM: The role of rebamipide in the management of inflammatory disease of the gastrointestinal tract. Aliment Pharmacol Ther 18 (Suppl 1):8-13, 2003
19. Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A: Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci 43 (Suppl 9):5S-13S, 1998
20. Makiyama K, Takeshima F, Kawasaki H, Zea-Iriarte WL: Anti-inflammatory effect of rebamipide enema on proctitis type ulcerative colitis: A novel therapeutic alternative. Am J Gastroenterol 95:1838-1839, 2000
21. Farup PG, Hinterleitner TA, Lukas M, Hebuterne X, Rachmilewitz D, Campieri M, Meier R, Keller R, Rathbone B, Oddsson E: Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis 7:237-242, 2001
22. Rachmilewitz D on behalf of an international study group: Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. Br Med J 298:82-86, 1989
23. Floren C-H, Benoni C, Willen R: Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scand J Gastroenterol 22:459-462, 1987
24. Matts SGF: The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med, New Ser XXX 120:393-407, 1961
25. Hanauer SB, Present DH: The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 3:81-92, 2003
26. Kornbluth A, Marion JF, Salomon P, Janowitz HD: How effective is current medical therapy for severe ulcerative colitis and Crohn's colitis? An analytic review of selected trials. J Clin Gastroenterol 20:280-284, 1995
27. Azad Khan AK, Piris J, Truelove SC: An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2:892-895, 1977
28. Kleine A, Kluge S, Peskar BM: Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci 38:1441-1449, 1993
29. Arakawa T, Watanabe T, Fukuda T, Yamasaki K, Kobayashi K: Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer: Comparison with cimetidine. Dig Dis Sci 40:2469-2472, 1995
30. Bamba H, Ota S, Kato A, Miyatani H, Kawamoto C, Yoshida Y, Fujiwara K: Effect of rebamipide on prostaglandin receptors-mediated increase of inflammatory cytokine production by macrophages. Aliment Pharmacol Ther 18 (Suppl 1):113-118, 2003
31. Tarnawski A, Arakawa T, Kobayashi K: Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats. One mechanism for its ulcer healing action? Dig Dis Sci 43:90S-98S, 1998
32. Aihara M, Imagawa K, Funakoshi Y, Ohmoto Y, Kikuchi M: Effects of rebamipide on production of several cytokines by human peripheral blood mononuclear cells. Dig Dis Sci 43 (Suppl 9):160S-166S, 1998
33. Shimada S, Inoue K, Kuramoto M, Suzuki S, Yamamoto K, Ogawa M: Preoperative administration of rebamipide significantly lowers body temperature and circulating interleukin-6 in gastric cancer patients after gastrectomy. Dig Surg 20:500-505, 2003
34. Aihara M, Azuma A, Takizawa H, Tsuchimoto D, Funakoshi Y, Shindo Y, Ohmoto Y, Imagawa K, Kikuchi M, Mukaida N, Matsushima K: Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lines. Dig Dis Sci 43 (Suppl 9):174S-180S, 1998
35. Marshall JK, Irvine EJ: Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 40:775-781, 1997
36. Cohen RD, Woseth DM, Thisted RA, Hanauer SB: A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 95:1263-1276, 2000
37. Sinha A, Nightingale JMD, West KP, Berlanga-Acosta J, Playford RJ: Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 349:350-357, 2003